Literature DB >> 11324784

Systemic lupus erythematosus in three ethnic groups. VII [correction of VIII]. Predictors of early mortality in the LUMINA cohort. LUMINA Study Group.

G S Alarcón1, G McGwin, H M Bastian, J Roseman, J Lisse, B J Fessler, A W Friedman, J D Reveille.   

Abstract

OBJECTIVE: To determine the features associated with mortality in a multiethnic US cohort of patients with systemic lupus erythematosus (SLE) within 5 years of study onset.
METHODS: Socioeconomic and demographic features (age, gender, ethnicity, marital status, education, occupation, poverty, and health-related behaviors [drinking, smoking, exercising]), clinical and immunologic features (disease duration, disease onset type, disease activity according to the Systemic Lupus Activity Measure [SLAM], disease damage according to the Systemic Lupus International Collaborating Clinics [SLICC] Damage Index [SDI], number of American College of Rheumatology criteria at diagnosis, organ system manifestations, fatigue and pain ratings, and medication usage and autoantibodies), immunogenetic features (HLA class II genotypes), and behavioral and psychosocial features (social support, illness-related behaviors, and helplessness), as obtained at enrollment into the study, were compared between survivors and deceased patients. Logistic regression analysis was used to determine significant independent risk factors for mortality.
RESULTS: Within 5 years of study onset, 34 of 288 patients have died. Fourteen deaths could be directly attributed to SLE and 11 to infections. In 1 patient the cause of death could not be determined. In the remaining 8 patients the cause of death was neither infectious nor disease-related. There were 10 deaths among Hispanics, 18 among African Americans, and 6 among Caucasians (P < 0.05). Variables associated with mortality in the univariable analyses included poverty, less than full-time employment, difficulty in accessing health care, shorter disease duration, cardiovascular and renal involvement, higher serum creatinine levels and lower hematocrit values, higher SLAM and SDI scores, lower use of antimalarial drugs, and higher use of (some) immunosuppressants. Specific autoantibodies and class II HLA genotypes were not associated with mortality. Poverty and higher baseline SLAM and SDI scores were independently associated with mortality in the multivariable analyses.
CONCLUSIONS: Disease activity, disease damage, and poverty appear to be the most important determinants of mortality in this multiethnic US cohort of SLE patients. These results have applicability to the management of patients with SLE, a disease that more severely affects disadvantaged minority population groups.

Entities:  

Mesh:

Year:  2001        PMID: 11324784     DOI: 10.1002/1529-0131(200104)45:2<191::AID-ANR173>3.0.CO;2-2

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  80 in total

1.  Role of community and individual characteristics in physician visits for persons with systemic lupus erythematosus.

Authors:  Chris Tonner; Laura Trupin; Jinoos Yazdany; Lindsey Criswell; Patricia Katz; Edward Yelin
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-06       Impact factor: 4.794

Review 2.  Ethnic disparities in patients with systemic lupus erythematosus.

Authors:  América G Uribe; Graciela S Alarcón
Journal:  Curr Rheumatol Rep       Date:  2003-10       Impact factor: 4.592

Review 3.  Lupus and pregnancy: complex yet manageable.

Authors:  Josephine Patricia Dhar; Robert J Sokol
Journal:  Clin Med Res       Date:  2006-12

4.  Prevalence of systemic lupus erythematosus and associated comorbidities in Puerto Rico.

Authors:  María J Molina; Angel M Mayor; Alejandro E Franco; Carlos A Morell; Miguel A López; Luis M Vilá
Journal:  J Clin Rheumatol       Date:  2007-08       Impact factor: 3.517

5.  Renal damage is the most important predictor of mortality within the damage index: data from LUMINA LXIV, a multiethnic US cohort.

Authors:  Maria I Danila; Guillermo J Pons-Estel; Jie Zhang; Luis M Vilá; John D Reveille; Graciela S Alarcón
Journal:  Rheumatology (Oxford)       Date:  2009-02-20       Impact factor: 7.580

6.  Seizures in patients with systemic lupus erythematosus: data from LUMINA, a multiethnic cohort (LUMINA LIV).

Authors:  R M Andrade; G S Alarcón; L A González; M Fernández; M Apte; L M Vilá; G McGwin; J D Reveille
Journal:  Ann Rheum Dis       Date:  2007-09-17       Impact factor: 19.103

Review 7.  Update on Antiphospholipid Syndrome: Ten Topics in 2017.

Authors:  Ilaria Cavazzana; Laura Andreoli; Maarteen Limper; Franco Franceschini; Angela Tincani
Journal:  Curr Rheumatol Rep       Date:  2018-03-15       Impact factor: 4.592

8.  Association of socioeconomic and demographic factors with utilization of rheumatology subspecialty care in systemic lupus erythematosus.

Authors:  Jinoos Yazdany; JoAnn Zell Gillis; Laura Trupin; Patricia Katz; Pantelis Panopalis; Lindsey A Criswell; Edward Yelin
Journal:  Arthritis Rheum       Date:  2007-05-15

9.  Patient-Reported Outcomes Predict Mortality in Lupus.

Authors:  Desiree R Azizoddin; Meenakshi Jolly; Shilpa Arora; Ed Yelin; Patricia Katz
Journal:  Arthritis Care Res (Hoboken)       Date:  2019-07-13       Impact factor: 4.794

10.  Prevalence, incidence, and demographics of systemic lupus erythematosus and lupus nephritis from 2000 to 2004 among children in the US Medicaid beneficiary population.

Authors:  Linda T Hiraki; Candace H Feldman; Jun Liu; Graciela S Alarcón; Michael A Fischer; Wolfgang C Winkelmayer; Karen H Costenbader
Journal:  Arthritis Rheum       Date:  2012-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.